Cannabinoids for Treatment of MS Symptoms: State of the Evidence

  • Jessica Rice
  • Michelle CameronEmail author
Demyelinating Disorders (J Bernard and M Cameron, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Demyelinating Disorders


Purpose of Review

Cannabis and cannabinoids have been used medically and recreationally for thousands of years and recently there has been a growing body of research in this area. With increased access now that medical marijuana is available in many jurisdictions, patients and providers want to know more about the evidence for benefits and risks of cannabinoid use. This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the use of cannabinoids for treating spasticity and pain associated with multiple sclerosis (MS), and a discussion of possible dosing regimens based on information from these studies.

Recent Findings

Two recent high-quality systematic reviews concluded that the only strong evidence for medical marijuana in neurological disorders was for reducing the symptoms of patient-reported spasticity and central pain in MS and that the only complementary and alternative medicine (CAM) intervention in MS with strong supportive evidence was cannabinoids. Based on this review, they concluded that nabiximols (Sativex oral spray), oral cannabis extract (OCE), and synthetic tetrahydrocannabinol (THC) are probably effective at reducing patient-reported symptoms of spasticity in people with MS, but OCE and synthetic THC were not found to be effective for reducing physician-administered measures of spasticity. In addition, nabiximols, OCE, and synthetic THC are probably effective at reducing MS-related pain. Cannabinoids were generally well-tolerated. However, cannabis use has been associated with an increased risk of psychosis and schizophrenia in at-risk individuals, there is growing evidence that cannabis can increase the risk for cardiovascular diseases, including myocardial infarction (MI), hypertension, heart failure, and stroke, and a recently recognized adverse effect of cannabis is cannabinoid hyperemesis syndrome.


The medical use of cannabinoids remains controversial. While cannabinoids have been studied for a variety of neurologic disorders, there is strongest evidence to indicate benefits in treatment of spasticity and neuropathic pain in multiple sclerosis. Although the best dose for an individual remains uncertain, most participants in the studies discussed in this paper used between 20 and 40 mg of THC a day in divided doses. Adverse events in studies were generally more common in the groups using cannabinoid products but serious adverse events were rare and cannabis products were generally well-tolerated. Cannabis use does appear to be associated with increased risk of certain adverse events, including psychosis, cardiovascular diseases, and cannabinoid hyperemesis syndrome.


Multiple sclerosis Cannabis Cannabinoid Spasticity Pain 


Compliance with Ethical Standards

Conflict of Interest

Jessica Rice declares no potential conflicts of interest.

Michelle Cameron is a section editor for Current Neurology and Neuroscience Reports. Dr. Cameron reports personal fees from Adamas and a grant from Greenwich Biosciences.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, et al. Perspectives on marijuana use and effectiveness: a survey of NARCOMS participants. Neurol Clin Pract. 2017;7:333–43.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Andre CM, et al. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Van der Pol P, et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction. 2014 Jul;109(7):1101–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Pertwee R. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;30(Suppl 1):S13–8.CrossRefGoogle Scholar
  6. 6.
    • Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556–63. Systematic review on the safety and efficacy of medical marijuana in MS, epilepsy, and movement disorders that included in their conclusions that certain cannabinoid preparations are effective or probably effective for MS-related spasticity, pain, and bladder symptoms but not tremor. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Americans for Safe Access. Legal Information By State & Federal Law. Accessed 15 Sept 2017.
  8. 8.
    Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313(24):2491–3.CrossRefPubMedGoogle Scholar
  9. 9.
    MARINOL [package insert]. North Chicago, IL: AbbVie Inc.Google Scholar
  10. 10.
    CESAMET [package insert]. Somerset, New Jersey: Meda Pharmaceuticals Inc.Google Scholar
  11. 11.
    GW Pharmaceuticals. Sativex prescriber Information. Accessed Sept 15, 2017.
  12. 12.
    International Association for Cannabinoids Medicines. Cannador. Accessed 15 Sept 2017.
  13. 13.
    • Yadav V, Bever C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083–92. American Academy of Neurology evidence-based guideline on complementary and alternative medicine in MS that included in their recommendations that clinicians might offer certain cannabinoid preparations for spasticity, pain, and urinary frequency but not tremor. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589–95.CrossRefPubMedGoogle Scholar
  15. 15.
    Fu, et al. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clin Rehabil. 2018;1:269215517745348.Google Scholar
  16. 16.
    Pandyan AD, Johnson GR, Price CIM, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth scales as measures of spasticity. Clin Rehabil. 1999;13(5):373–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–26.CrossRefPubMedGoogle Scholar
  18. 18.
    Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, on behalf of the MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Collin C, Davies P, Mutiboko IK, Ratcliffe S, for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–31.CrossRefPubMedGoogle Scholar
  24. 24.
    • Whiting PF, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73. This comprehensive systematic review and meta-analysis for the use of cannabinoids in all medical conditions, not limited to multiple sclerosis or neurologic conditions, included in its conclusions that there was moderate quality evidence to support use of cannabinoids for the treatment of chronic pain and spasticity. CrossRefPubMedGoogle Scholar
  25. 25.
    Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154(5):632–42.CrossRefPubMedGoogle Scholar
  26. 26.
    Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life Sci. 1999;65(6–7):665–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A. 1995;92(8):3376–80.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16(1):149–59.CrossRefPubMedGoogle Scholar
  30. 30.
    Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136–48.CrossRefPubMedGoogle Scholar
  31. 31.
    Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506–21.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735–44.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Lynch ME, Ware MA. Cannabinoids for treatment of chronic non-cancer pain: an updated systematic review of randomized trials. J NeuroImmune Pharmacol. 2015;10:293–301.CrossRefPubMedGoogle Scholar
  34. 34.
    • Ware MA, et al. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;16(12):1233–42. This is the only currently published study focusing on the safety of cannabinoids when used in the management of chronic pain. The study found a higher rate of adverse events, but not serious adverse events, among users of 2.5g of herbal cannabis/day compared to non-users. CrossRefPubMedGoogle Scholar
  35. 35.
    Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19:187–94.CrossRefPubMedGoogle Scholar
  36. 36.
    Zammit, et al. Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord. 2016;195:63–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Honarmand K, et al. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology. 2012;76(13):1153–60.CrossRefGoogle Scholar
  39. 39.
    Pavisian B, MacIntosh BJ, Szilagyi G, Staines RW, O’Connor P, Feinstein A. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology. 2014;82(21):1879–87.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Jouanjus E, Lapeyre-Mestre M, Micallef J, The French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications*. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 2014;3(2):e000638.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V. What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review. Curr Atheroscler Rep. 2017;19(6):26.CrossRefPubMedGoogle Scholar
  42. 42.
    Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103:2805–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Cut. 2004;53(11):1566–70.Google Scholar
  44. 44.
    Chen J, et al. Cannabinoid hyperemesis syndrome: a result of chronic, heavy cannabis use. Curr Psychiatr. 2013;12(10):48–54.Google Scholar
  45. 45.
    Jones JI, et al. Successful treatment of suspected cannabinoid hyperemesis syndrome using haloperidol in the outpatient setting. Case Rep Psychiatr. 2016;2016(3614053):1–3.Google Scholar
  46. 46.
    Grotenhermen F, Russo E. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton: The Haworth Press. p. 2002.Google Scholar
  47. 47.
    Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJA, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17(5):293–306.CrossRefPubMedGoogle Scholar
  48. 48.
    Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585–614.CrossRefPubMedGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  1. 1.Oregon Health & Science UniversityPortlandUSA

Personalised recommendations